N-Myc Proto-Oncogene Protein

A basic helix-loop-helix leucine zipper (bHLHZ) transcription factor and proto-oncogene protein that functions in cell growth and proliferation. In mammals, it is highly expressed in the brain during embryogenesis and is essential for brain development; it is not expressed in adult tissues. Amplification or overexpression of N-Myc occurs in at least 20% of tumors and is associated with a poor prognosis in cases of NEUROBLASTOMA; ALVEOLAR RHABDOMYOSARCOMA; SMALL CELL LUNG CARCINOMA; and neuroendocrine prostate cancer.

Also Known As:

Networked: 108 relevant articles (0 outcomes, 7 trials/studies)

Bio-Agent Context: Research Results

Experts

1.	Liu, Tao: 7 articles (01/2021 - 06/2011)
2.	Maris, John M: 6 articles (01/2021 - 03/2013)
3.	Marshall, Glenn M: 6 articles (01/2021 - 06/2011)
4.	Shimada, Hiroyuki: 6 articles (01/2021 - 03/2013)
5.	Ikegaki, Naohiko: 5 articles (01/2021 - 10/2013)
6.	Suenaga, Yusuke: 5 articles (01/2020 - 12/2009)
7.	Fischer, Matthias: 5 articles (12/2019 - 05/2010)
8.	Chesler, Louis: 5 articles (11/2016 - 08/2006)
9.	Cheung, Belamy B: 4 articles (01/2021 - 11/2019)
10.	Cohn, Susan L: 4 articles (01/2021 - 03/2013)

Related Diseases

1.	Neuroblastoma 03/01/2020 - "Our study showed a novel coordinately prognostic role of ALK and MYCN protein expression in neuroblastoma and is the first report to demonstrate the correlation between ALK and MYCN protein expression in primary neuroblastoma tumours." 06/30/2015 - "Augmented expression of MYC and/or MYCN protein defines highly aggressive MYC-driven neuroblastoma: a Children's Oncology Group study." 10/01/2000 - "Our current studies focused on identifying N-myc target genes, especially those affected in cells such as neuroblastomas that have high levels of N-myc protein. " 10/16/1997 - "These studies provide the first systematic investigation of autoregulation in neuroblastoma, and indicate that single-copy neuroblastoma lines produce insufficient N-Myc protein to activate downstream effector(s) of autosuppression; the autoregulatory circuit is otherwise intact. " 10/01/1991 - "This study was undertaken to determine the pattern of MYCN protein (pMYCN) phosphorylation in human neuroblastoma cells. "
2.	Carcinogenesis 11/01/2019 - "Enhanced MYCN protein stability is a key component of MYCN oncogenesis and is maintained by multiple feedforward expression loops involving MYCN transactivation target genes. " 07/01/2010 - "We found that Nmyc was specifically required in granule cells for Shh-induced tumorigenesis and that Dex acted to reduce Nmyc protein levels. " 04/02/2009 - "Taken together our data identify N-Myc protein stability as the result of loss of Ptch1, which distinguishes normal cerebellar development from medulloblastoma tumorigenesis." 06/01/2011 - "SIRT1 promotes N-Myc oncogenesis through a positive feedback loop involving the effects of MKP3 and ERK on N-Myc protein stability." 11/05/2019 - "This study therefore identifies lncNB1 and its binding protein RPL35 as key factors for promoting E2F1 protein synthesis, N-Myc protein stability and N-Myc-driven oncogenesis, and as therapeutic targets."
3.	Neoplasms (Cancer) 10/18/2023 - "Based on features including tumor staging, N-myc proto-oncogene protein (MYCN) amplification status, histology, most were deemed intermediate or high risk. " 11/01/2022 - "In contrast, if patients with MYCN non-amplified tumors were positive for MYCN protein, they had a poor prognosis. " 01/01/2022 - "Overall, our results strengthen the view of N-MYC as a therapeutic target in GBM and strongly suggest that IDP-410 could be further developed to become a first-in-class inhibitor of N-MYC protein, affecting not only tumor cell proliferation and survival, but also the interplay between GBM cells and their microenvironment." 01/01/2022 - "Moreover, enhanced ROS production destabilizes N-MYC protein by inhibiting AKT signaling and is responsible for the reduced survival of NEPC cells and tumors. " 10/10/2021 - "Finally, we show that FOXR2 binds and stabilizes MYCN protein and MYCN protein levels are highly increased in FOXR2-expressing tumors, in several cases comparable with MYCN-amplified samples. "
4.	Retinoblastoma (Glioblastoma, Retinal) 12/01/2022 - "Additionally, ∼2% lack RB1 mutations but have MYCN amplification (MYCNA), N-Myc protein overexpression, and more rapid and invasive growth, yet the MYCNA retinoblastoma cell of origin and basis for its responses to deregulated N-Myc are unknown. " 12/01/2020 - "Knockdown of MYCNOS1 caused instability of the MYCN protein, leading to cell cycle arrest and impaired proliferation and chemotaxis-directed migration in MYCN-amplified retinoblastoma cells in which RB1 was intact. " 10/01/1993 - "Activation of gene transcription by the amino terminus of the N-Myc protein does not require association with the protein encoded by the retinoblastoma suppressor gene RB1." 10/01/2021 - "Excised tumors revealed that DFMO/probenecid treatment decreases polyamines putrescine and spermidine, reduces MYCN protein levels and dephosphorylates retinoblastoma (Rb) protein (p-RbSer795), suggesting DFMO/probenecid-induced cell cycle arrest. "
5.	Medulloblastoma 04/02/2009 - "Patched1 deletion increases N-Myc protein stability as a mechanism of medulloblastoma initiation and progression." 03/01/2001 - "ABC immunostaining was used to detect C-myc and N-myc protein expression in 21 cases of adulthood medulloblastomas and 14 childhood cases. " 03/01/2001 - "[Expression of C-myc and N-myc protein in adulthood and childhood medulloblastomas and prognostic analysis]." 06/01/1989 - "Of the 12 medulloblastoma samples collected over a two-year period and analysed in the course of this project, a trend towards longer disease-free survival was noted in the patients having low levels of the N-myc protein in their tumour." 04/02/2009 - "Taken together our data identify N-Myc protein stability as the result of loss of Ptch1, which distinguishes normal cerebellar development from medulloblastoma tumorigenesis."

Related Drugs and Biologics

1.	Proteins (Proteins, Gene)
2.	Messenger RNA (mRNA)
3.	Carrier Proteins (Binding Protein)
4.	MicroRNAs (MicroRNA)
5.	Tretinoin (Retinoic Acid)
6.	Aurora Kinase A
7.	Small Interfering RNA (siRNA)
8.	Biomarkers (Surrogate Marker)
9.	Tetracycline (Achromycin)
10.	Serine (L-Serine)

Related Therapies and Procedures

1.	Therapeutics